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Background: Central neuropathic pain represents one of the most common symptoms
in multiple sclerosis (MS) and it seriously affects quality of life. Spinal mechanisms
may contribute to the pathogenesis of neuropathic pain in MS. Converging evidence
from animal models and neurophysiological and clinical studies in humans suggests a
potential effect of transcranial direct current stimulation (tc-DCS) on neuropathic pain.
Spinal application of DCS, i.e., transcutaneous spinal DCS (ts-DCS), may modulate
nociception through inhibition of spinal reflexes. Therefore, ts-DCS could represents
an effective, safe and well-tolerated treatment for neuropathic pain in MS, a largely
unexplored topic. This study is a pilot randomized double-blind sham-controlled trial
to evaluate the efficacy of ts-DCS on central neuropathic pain in MS patients.
Methods: Thirty-three MS patients with central neuropathic pain were enrolled and
randomly assigned to two groups in a double-blind sham-controlled design: anodal
ts-DCS group (n = 19, 10 daily 20-min sessions, 2 mA) or sham ts-DCS group (n = 14,
10 daily 20-min sessions, 0 mA). The following clinical outcomes were evaluated before
ts-DCS treatment (T0), after 10 days of treatment (T1) and 1 month after the end of
treatment (T2): neuropathic pain symptoms inventory (NPSI), Ashworth Scale (AS) for
spasticity and Fatigue Severity Scale (FSS). A subgroup of patients treated with anodal
ts-DCS (n = 12) and sham ts-DCS (n = 11) also underwent a parallel neurophysiological
study of the nociceptive withdrawal reflex (NWR) and the NWR temporal summation
threshold (TST), two objective markers of pain processing at spinal level.
Results: Anodal ts-DCS group showed a significant improvement in NPSI at T1, which
persisted at T2, while we did not detect any significant change in AS and FSS. Sham
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ts-DCS group did not show any significant change in clinical scales. We observed a
non-significant trend towards an inhibition of NWR responses in the anodal ts-DCS
group at T1 and T2 when compared to baseline.
Conclusions: Anodal ts-DCS seems to have an early and persisting (i.e., 1 month after
treatment) clinical efficacy on central neuropathic pain in MS patients, probably through
modulation of spinal nociception.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier #NCT02331654.
Keywords: neuropathic pain, transcutaneous spinal direct current stimulation (ts-DCS), non-invasive, nociceptive
withdrawal reflex, neuromodulation, multiple sclerosis
INTRODUCTION
Pain represents one of the most disabling symptoms of multiple
sclerosis (MS), in that it adversely affects most aspects of health-
related quality of life and is often neglected and undertreated.
The overall prevalence of pain syndromes in MS patients is
63% (Foley et al., 2013), with a higher risk associated with
older age, longer disease duration, and greater disease severity
(Solaro et al., 2004). A recent multicenter cross-sectional study
on 1,249 MS patients reported a 33.8% overall frequency of
pain (Solaro et al., 2018). Central neuropathic pain, defined as
a pain that is directly caused by a lesion or disease involving
the somatosensory system (Treede et al., 2008), is the main
type category of MS-related pain and it can be distinguished in
three main forms: central neuropathic (‘‘dysesthetic’’) extremity
pain, trigeminal neuralgia and Lhermitte’s sign (O’Connor et al.,
2008).
Central neuropathic extremity pain is described as a
continuous burning, tingling or aching pain, unilateral or
bilateral in distribution, affecting legs and feet, even in the
early stages of the disease. This type of pain is thought to be
caused by lesions in brain and spinal cord nociceptive pathways
leading to a dysregulation in inhibitory and/or excitatory
pain mechanisms, including GABA-ergic interneurons and
NMDA receptors (Olechowski et al., 2013). This type of
MS-related pain has a prevalence ranging from 16 to 26% (Foley
et al., 2013; Solaro et al., 2018) and its treatment remains a
significant challenge as available therapies are scarcely effective
or poorly tolerated (O’Connor et al., 2008; Paolucci et al.,
2016).
Patients with MS may also report nociceptive types of pain
that include painful tonic spasms related to corticospinal tract
involvement, musculoskeletal and back pain (Solaro et al., 2004,
2018).
Transcranial direct current stimulation (tc-DCS) represents
a non-invasive, safe and well tolerated method for selectively
modulating cortical excitability in a polarity-dependent way.
Tc-DCS was documented to have an impact on a range of motor
(Nitsche and Paulus, 2001; Nitsche et al., 2005), somatosensory
(Rogalewski et al., 2004; Grundmann et al., 2011), visual
(Antal et al., 2006), affective and cognitive functions (Kincses
et al., 2004; Boggio et al., 2008) and it has received increased
attention regarding potential therapeutic applications in the
fields of neurology and psychiatry. Up to now, the therapeutic
effects of tc-DCS are considered promising for fibromyalgia
and major depressive disorders and emerging evidence has
underlined its great potential efficacy in pain conditions (Antal
et al., 2008; Boggio et al., 2008; Csifcsak et al., 2009; Hansen
et al., 2011). However, convincing evidence on the efficacy
of tc-DCS of the motor cortex in chronic pain conditions
needs is still missing (O’Connell et al., 2011). Anodal tc-DCS
of the left motor cortex, or contralateral to the pain side,
with right orbitofrontal cathode, has indeed received a level C
recommendation (i.e., possible efficacy) in chronic lower limb
neuropathic pain secondary to spinal cord lesion (Lefaucheur
et al., 2017).
The spinal application of DCS, defined as transcutaneous
spinal direct current stimulation (ts-DCS), may represent
a non-invasive, safe, non-pharmacological and potentially
self-administered approach to those conditions where pain
is generated or becomes chronic through changes in spinal
interneurons. In humans, anodal ts-DCS has been proven to
inhibit nociceptive specific responses, such as the nociceptive
withdrawal reflex (NWR; Cogiamanian et al., 2011) and the
NWR temporal summation threshold (TST; Perrotta et al., 2016).
The hypothesized mechanism involved in the modulation of
the NWR responses could be direct or supraspinal-mediated
change in excitability of spinal sensory neurons, including the
wide dynamic range (WDR) neurons mediating short-term
NMDA-mediated plasticity, which is involved in the spinal cord
pain processing as well as in and the genesis and maintenance of
chronic pain (Perrotta et al., 2016).
Based on these pieces of evidence, ts-DCS might be a valuable
therapeutic approach in subjects with MS and diagnosed with
central neuropathic extremity pain. However, the efficacy of
ts-DCS in this type of pain has been seldom investigated in
humans.
Aim of the Study
The aim of this pilot multi-center randomized controlled trial
(RCT) is to evaluate the short and middle-term effect of
treatment with anodal ts-DCS on central neuropathic extremity
pain inMS, using clinical scales and neurophysiological measures
of spinal nociception. We focused on central neuropathic
extremity pain, because it is by far the most common type of
neuropathic pain in MS (Foley et al., 2013; Solaro et al., 2018).
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The primary outcome measure was neuropathic pain severity,
and the secondary endpoints were the neurophysiological
measures derived from the NWR. Other secondary measures
included spasticity and fatigue.
MATERIALS AND METHODS
This was a multicentric study carried out in accordance
with the Guidelines for Good Clinical Practice. The protocol
was approved by the Ethics Committee of the Coordinating
Center (Mondino Foundation, Approval number: 2786/13)
and subsequently approved by the Local Institutional Ethical
Committees of the participating centers. Before enrollment, all
subjects gave their written informed consent in accordance with
the Declaration of Helsinki.
Subjects
Thirty-three subjects (25 female and 8 male) with a
definite diagnosis of MS according to McDonald criteria
(Polman et al., 2011), and suffering from neuropathic
pain of the lower limbs, were recruited in a double-
blind, placebo-controlled, multicenter study design
(NCT02331654).
Neuropathic pain was diagnosed according to the grading
system (Treede et al., 2008) and the Douleur Neuropathique
Questionnaire 4 (DN4; Bouhassira et al., 2005). Patients were
diagnosed as suffering from definite central neuropathic
extremity pain when other likely causes of pain were
excluded, pain had a plausible neuroanatomical distribution
confirmed by clinical findings, the DN4 score was ≥4 and
neuroimaging showed a demyelinating lesion consistent
with the pain distribution (Treede et al., 2008; Solaro et al.,
2018).
Patients were recruited at the IRCCS C. Mondino Foundation
in Pavia, Santa Lucia Foundation in Rome, IRCCS ‘‘Neuromed’’
Institute in Pozzilli and Don Gnocchi Foundation inMilan, Italy.
Relapsing-remitting (RR), secondary-progressive (SP) and
primary-progressive (PP) MS patients were enrolled in a
follow-up procedure that included a general and neurological
evaluation scored according to the Expanded Disability Status
Scale of Kurtzke and its functional systems (Kurtzke, 1983). RR
patients were evaluated in a stationary phase of the disease, at
least 2 months after the last clinical relapse and at least 1 month
after the end of a steroidal treatment.
For all participants, exclusion criteria were: (a) other
neurological disorders, including primary or secondary
headaches; (b) clinical or family history of neurological
disorders; (c) any systemic or psychiatric disorder; (d) Beck
Depression Inventory (BDI) scale score >9; (e) cognitive
impairment (Mini Mental State Examination < = 24); (f)
use of analgesics or steroids in the previous 24 h; (g) clinical
or instrumental (including MRI) evidence of any central
or peripheral disease/lesion potentially causing sensory
impairment, including spinal lesions at lumbar level; (h)
fibromyalgia; (i) complex regional pain syndrome; (j) chronic
low back pain and other pain conditions not related to
MS; and (k) changes in the schedule or dose of Disease
Modifying Drugs (DMDs) for MS, antidepressants, antiepileptic
drugs, tetrahydrocannabinol/cannabidiol or any other drug
that may have a definite or potential effect on pain in
the previous 3 months. Patients were excluded from the
study if:
- any change in the schedule or dose of drugs listed at point (l)
above became necessary at any time during the observation
period.
- they had taken analgesics or steroids in the 24 h before the
clinical and neurophysiological evaluations.
Patients were randomly assigned to two groups: 19 patients
were assigned to the anodal ts-DCS treatment group and
14 patients to the sham ts-DCS group. A subgroup of 12 patients
treated with anodal ts-DCS and 11 patients treated with sham
ts-DCS also underwent the neurophysiological evaluation of the
NWR (see below).
Transcutaneous Spinal Direct Current
Stimulation (ts-DCS)
Anodal and sham ts-DCS was delivered by a constant direct
current electrical stimulator (HDCstim, Newronika s.r.l., Milan,
Italy) connected to a pair of electrodes: the anode was placed
on the thoracic spinal cord (over the spinal process of the
tenth thoracic vertebra) and the cathode (reference) on the
right shoulder in the suprascapular region. Stimulating electrodes
consisted in 1-mm thick, rectangular (7 × 5 cm), rubber
membranes, enveloped in a saline-soaked sponge. Conducting
surface was 35 cm2 for both active and reference electrode.
Electrodes were fixed inside by elastic customized stripes.
For the real anodal ts-DCS group, we delivered a 2 mA
constant direct current for 20 min in each session with a
density of 0.071 mA/cm2 and delivered a total charge of
63.9 mC/cm2. These parameters are far below both the threshold
for tissue damage and the conscious sensory threshold, apart
from transient, and short-lasting tingling sensation below the
electrodes at the start of the stimulation.
For the sham ts-DCS group, electrodes were placed in the
same spots than real anodal stimulation, but the stimulator was
programmed to automatically turn to 0 mA after 10 s.
We based the choice of the stimulation site and the related
stimulation parameters on the results of our previous study in
healthy subjects in which we demonstrated the effectiveness of
the tsDCS in modulating the TST of the NWR (Perrotta et al.,
2016).
The treatment protocol consisted of 10 daily 20-min sessions
of active or sham ts-DCS delivered over a 2-week period
(from Monday to Friday) and a follow-up period of 4 weeks.
Patients and assessing physicians were blind to group allocation;
stimulator programming and electrodes applications were made
by physicians not involved in the enrollment, clinical and
neurophysiological evaluation, and data analysis.
Clinical Assessments
Patients were evaluated with clinical scales at baseline (T0), at the
end of the 2-week treatment period (T1) and at 1 month from
the end of treatment (T2). Characteristics and intensity of pain
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symptoms were collected at each stage with the Validated Italian
Version of Neuropathic Pain Symptoms Inventory (NPSI; Padua
et al., 2009). Spasticity of lower legs, if present, was assessed with
the Ashworth Scale (AS; Pandyan et al., 1999). The presence and
severity of fatigue was assessed by means of the Fatigue Severity
Scale (FSS; Krupp et al., 1989).
Neurophysiological Testing: Sensory
Threshold, Nociceptive Withdrawal Reflex
Threshold and Temporal Summation
Threshold
In parallel with clinical evaluation, the previously described
subgroup of MS patients underwent a neurophysiological testing
that included sensory threshold (Sth), NWR threshold (Rth),
area under curve response (Area) and NWR TST and was
administered at T0, T1 and T2.
The NWR from the lower limbs was investigated according
to a previously described and validated method (Sandrini et al.,
2005). Subjects were seated in a comfortable armchair in a quiet
room at constant temperature. Their lower limbs were positioned
to ensure complete muscle relaxation with knee flexed at 130◦
and ankle at 90◦.
The sural nerve was stimulated percutaneously via a pair of
standard Ag/AgCl surface electrodes applied to degreased skin
behind the right lateral malleolus. The stimulus consisted of
20 ms current pulse train of five individual 1 ms rectangular
pulses delivered at 200 Hz (equal to an inter-stimulus interval
of 4 ms). Electromyographic reflex responses were recorded
from the capitis brevis of the biceps femoris muscle via a
standard pair of Ag/AgCl surface electrodes. The analysis time
was 300 ms, with the sensitivity set at 100 mV, the filter bandpass
setting was between 3 Hz and 3 kHz (CED Powerlab interface
1401, Cambridge Electronic Design, UK; electronic amplifier
BM623, Biomedica Mangoni, Italy; electric simulator DS7A,
Digitimer, UK).
In order to evaluate the efficiency of the sensory pathways,
the Sth was determined at the start of each experimental session.
The previously described pulse train, increased or decreased
in 0.1 mA steps were delivered at unpredictable intervals of
±10 s. Subjects were asked to indicate verbally the stimulation
levels at which they became aware of sensory sensations. The
sensory threshold was defined as the lowest stimulation intensity
generating a stable sensory sensation.
The staircase method was used to evaluate the Rth, defined
as the lowest stimulation intensity generating a clearly detectable
nociceptive reflex response exceeding 20 µV for 10 ms or
more in the time interval 80–130 ms over five pulse train
randomly delivered every 20–40 s and hence the related pain
perception. The intensity of stimulation was then fixed at 1.2 Th
and randomly delivered every 5–20 s to avoid habituation
phenomena. Each response was full-wave rectified and integrated
between set points from 80 to 130 ms after the start of the
test stimulus. Five reflex responses were recorded and the mean
NWR Area was computed by means of a computerized method.
To evaluate the NWR TST, the previously described
stimulation/recording setting was used. The pulse train of five
individual 1-ms pulses delivered at 200 Hz was repeated five
times at a frequency of 2 Hz. The stimulus intensity was
increased (in 1 mA steps) from 2 mA until detection of temporal
summation of the NWR. The NWR TST was defined as the
lowest stimulation intensity generating a stable NWR response
at the fourth and fifth pulse train of the five-train series
and exceeding 20 µV in the time interval between 80 and
130 ms for a period of more than 10 ms. A threshold was
accepted when three consecutive recordings resulted in the
same threshold. Subjects rated the subjective pain sensation
for each stimulus on a 0–11 numerical rating scale, (NRS,
graded from 0 = no pain to 10 = unbearable pain, with
pain sensation anchored to 5). The mean psychophysical pain
sensation at Th (NRS at Th) and at first (NRS1) and fifth
(NRS5) stimulus of the five delivered to evoke the TST was
calculated.
Data Analysis
The Statistical Package for the Social Sciences (SPSS) for
Windows, version 21.0, was used for the calculation. For
each variable we evaluated skewness and kurtosis to assess
normality. Moreover, the data were plotted using a ‘‘Q-Q plot’’
that confirmed normal distribution of all tested variables. For
qualitative variables we used cross-tabs analysis, performing
statistical significance with chi-square or Fisher exact test.
Quantitative variables are presented as mean values ± standard
deviation. To assess the intragroup acute effect, we used a
Student’s t-test for related samples or, in presence of multiple
time measurements, a repeated measures analyses of variance
(ANOVA) and post hoc with Bonferroni’s correction. To assess
differences between groups at each time point we used a Student’s
t-test for unpaired samples. The level of significance (α) was set
for convention as p = 0.05 for all the tests, and always corrected
where necessary.
TABLE 1 | Demographic and clinical characteristics of the active and sham
ts-DCS groups.
Demographic and clinical Active ts-DCS Sham ts-DCS p
characteristics (n = 19) (n = 14) value
Age (years) 57.6 ± 9.1 54.0 ± 7.79 n.s.
Sex n.s.
Men 4 (21.1%) 4 (28.6%)
Women 15 (78.9%) 10 (71.4%)
Multiple sclerosis type n.s.
Relapsing remitting 1 (5.3%) 3 (21.4%)
Secondary progressive 14 (73.7%) 10 (71.4%)
Primary progressive 4 (21.1%) 1 (7.1%)
Disease duration (years) 19.7 ± 8.8 15.9 ± 7.5
Relapsing remitting 16.0 ± 0.0 12.7 ± 5.7
Secondary progressive 24.5 ± 7.1 21.0 ± 9.3 n.s.
Primary progressive 18.6 ± 10.5 14.0 ± 0.0
EDSS score 5.9 ± 1.3 5.9 ± 1.2 n.s.
Pharmacological Treatments
Disease Modifying Drugs (DMDs) 7 (36.8%) 5 (35.7%)
Tetrahydrocannabinol/ Cannabidiol 3 (15.7%) 3 (21.4%) n.s.
Other drugs for neurophatic pain 8 (42.1%) 7 (50.0%)
Data are reported as mean ± SD or N (%). ts-DCS, transcutaneous spinal direct
current stimulation; EDSS, Kurtzke Expanded Disability Status Scale; n.s, not significant
(p value > 0.05).
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RESULTS
Demographic features and baseline parameters of participating
groups are reported in Table 1. No statistically significant
differences in clinical parameters were detected between groups
at T0.
Clinical Evaluation
In the active ts-DCS group, we found a significant reduction
in NPSI mean values (F(2,17) = 5.175; p = 0.013) at both
T1 (Bonferroni’s corrected paired t-test: p = 0.023) and T2
(p = 0.008) when compared to T0 (Table 2; Figure 1). No
significant differences were seen at any time point in AS and FSS
(Table 2).
In the sham ts-DCS group, we did not detect any significant
change in any of the clinical variables considered (i.e., NPSI, AS,
FSS; Table 2).
The intergroup analysis showed a significant improvement in
the NPSI score in the active ts-DCS group compared to the sham
ts-DCS group at both T1 (F(1,31) 4.194; p = 0.049) and T2 (F(1,31)
6.637; p = 0.015; Figure 1). AS and FSS scores did not differ
between groups at any time point.
Neurophysiological Evaluation
We observed a tendency towards an increase in the
neurophysiological parameters (Rth, NWR TST) in the active
ts-DCS group at T1 when compared to T0, suggesting a reduced
pain processing. However, no significant difference was found
in either active or sham ts-DCS groups when comparing the
neurophysiological and related psychophysical parameters
recorded at T1 or T2 with T0 values (Table 3). Similarly,
intergroup analysis did not show any significant change between
active and sham ts-DCS groups in Sth, Rth and TST at T0,
T1 and T2.
DISCUSSION
The main result of this study is that a 2-week period of
daily anodal ts-DCS at the thoracic level induced a significant
and persisting improvement in pain severity in patients
with MS and central neuropathic extremity pain. Indeed,
FIGURE 1 | NPSI Score in the active and sham ts-DCS Groups. Data are
reported as mean ± SD. ts-DCS, transcutaneous spinal direct current
stimulation; NPSI, Neuropathic Pain Symptoms Inventory. ∗Significant active
ts-DCS vs. sham ts-DCS comparison (p value < 0.05).
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the observed improvement in pain symptoms persisted for
further 4 weeks after the end of the stimulation period.
On the contrary, the sham stimulation did not influence
clinical parameters, (i.e., pain, spasticity and fatigue) in the
control group. Neurophysiological parameters, including Rth
and TST of the NWR, showed a parallel pattern to the clinical
findings when considering the T0 and T1 time point, although
the neurophysiological changes did not reach a statistically
significant level. Taken as a whole, these findings are in line
with previous reports of inhibition of pain reflex responses after
anodal ts-DCS in healthy subjects (Cogiamanian et al., 2011;
Perrotta et al., 2016), and of clinical improvement of central
neuropathic pain after tc-DCS in subjects with MS (Mori et al.,
2010).
Based on the present data, which showed ts-DCS to be
effective on MS-related neuropathic pain, and to partially
inhibit nociceptive reflex responses driven by WDR neurons,
we hypothesize that ts-DCS may modulate segmental or
intersegmental excitability in spinal nociceptive neurons, which
are likely to be theWDR neurons, as observed in healthy subjects
(Cogiamanian et al., 2011; Perrotta et al., 2016).
Spinal and trigeminal WDR neurons can plastically change
their excitability in a gradedmanner, as function of the frequency
and the intensity of the stimulation, in a phenomenon known as
wind-up (Liebetanz et al., 2002; Mendell and Wall, 1965). This
property of the WDR neurons induces a shift from tactile to
painful sensory processing, and it is considered to be pivotal in
physiological nociception for the discriminative analysis of pain
sensation (Herrero et al., 2000; Perrotta et al., 2017), and in the
pathogenesis of chronic pain for the induction and maintenance
of central sensitization (Li et al., 1999; Eide, 2000; Perrotta
et al., 2010). Thus, we speculate the parallel inhibition of NWR
TST in healthy subjects (Cogiamanian et al., 2011; Perrotta
et al., 2016) and the improvement of MS-related neuropathic
pain after ts-DCS to be a consequence of long-lasting WDR
neurons excitability depression. In addition, the excitability of
the WDR neurons is strictly associated to the activity of the
NMDA receptors (Dickenson and Sullivan, 1987; Guirimand
et al., 2000), which are likewise considered to be involved
in the pathogenesis of neuropathic pain in MS (Olechowski
et al., 2013). Based on the observation that cortical excitation
to both anodal and cathodal tc-DCS is prevented by NMDA
blockade (Liebetanz et al., 2002; Nitsche et al., 2003), we may
hypothesize the observed modulation of pain processing to
ts-DCS to be similarly caused by a change in NMDA receptor
activity at the spinal level. The lack of inhibitory effect of thoracic
ts-DCS on both evoked responses at cervical level (Cogiamanian
et al., 2008) and H-reflex excitability (Cogiamanian et al.,
2011), makes the involvement of supraspinal antinociceptive
descending projections and/or motoneuron inhibition quite
unlikely mechanisms of action.
However, a series of issues that have emerged from our
data need to be carefully considered and discussed. We
found a non-significant trend toward a TST depression in
the ts-DCS group. This finding could be related either to the
small sample size of the group undergoing neurophysiological
evaluation, or to specific features of our MS patients. MS
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is a complex disease and progressive forms of MS are
associated with neurodegeneration (Baecher-Allan et al., 2018).
Most patients in our study were affected by SP MS, had
a longer disease duration and spinal lesions. We speculate
that these features, which are frequently associated with
neurodegeneration and largely abnormal or unobtainable evoked
potentials, may have interfered with NWR modulation by ts-
DCS. However, though a comparison of the present NWR
findings to the few previously published ones is difficult, due
to sample sizes and methodological issues, our findings are
in line with the observed inhibition of the NWR responses
in MS patients treated with drugs for pain and spasticity
(e.g., topiramate, gabapentin, tetrahydrocannabinol/cannabidiol;
Conte et al., 2009; Foley et al., 2013). Some of our patients
were on tetrahydrocannabinol/cannabidiol, but the stability
of the dose (at least 3 months before enrolment and
across the entire study) suggest that intake of this drug is
unlikely to have influenced our clinical and neurophysiological
findings.
We could not document any significant change in spasticity
and fatigue scores to ts-DCS. This finding is in keeping with
previous controversial data on the effect of DCS on these two
outcomes (Palm et al., 2014; Iodice et al., 2017).
Indeed, previous reports yielded discordant data on the
effect of neuromodulation technique on spasticity (Khan et al.,
2017). A Cochrane review underlined a low-quality evidence
for the use of TMS in MS-related spasticity (Amatya et al.,
2013), and controversial data are reported on tc-DCS (Khan
et al., 2017). Few data about the effect of ts-DCS on muscle
tone are available (Ahmed, 2014), and none is specific for MS
patients.
In our opinion, the lack of effectiveness of ts-DCS on
motoneuron excitability (Cogiamanian et al., 2011), the complex
mechanisms involved in MS spasticity, and the specific features
of our MS patients (i.e., prevalence of SP forms and spinal
lesions) could explain the lack of effect of ts-DCS on spasticity.
Fatigue represents a frequent and invalidating symptom in
MS. MS fatigue is still considered the result of a multifactorial
and complex constellation, and is commonly classified into
‘‘primary’’ fatigue, i.e., related to the pathological MS changes,
and ‘‘secondary’’ fatigue, which is attributed to mimicking
symptoms, comorbid sleep and mood disorders, medications
side effects, spasticity, and pain (Chalah et al., 2015). Primary
fatigue is linked to brain atrophy and supraspinal lesions that
alter cortico-striato-thalamo-cortical connectivity. Evidence in
MS patients suggested that tc-DCS of the motor (Ferrucci et al.,
2014) or the sensory cortex (Tecchio et al., 2014) may improve
fatigue, especially the primary one or that related with mood
disorders. Recent studies suggest that ts-DCS could improve
fatigue resistance and enhance some physical performances
(e.g., vertical jump) in healthy subjects (Berry et al., 2017).
Possible reasons for the absence of significant effect of ts-DCS
on fatigue in our study may include the clinical features of
our patients (i.e., long duration of disease, presence of pain,
spasticity, and hypasthenia), which might be mainly related to
secondary fatigue, and the spinal site of stimulation. In contrast
to pain, only supraspinal mechanisms seem to be altered in
MS-related fatigue (Chalah et al., 2015), and this point could
explain the higher efficacy of tc-DCS than ts-DCS on this
symptom.
Limitations
This study was conducted on a small number of patients with
a long disease duration, who may not be representative of the
full population of MS patients and prevented us from stratifying
our population by disease form (i.e., RR, SP, or PR) or lesion
load site (i.e., mainly cortical or spinal). Further studies are
needed to evaluate the effect of ts-DCS on different types of
MS-related pain, either neuropathic or nociceptive. Moreover,
studies that stratify patients according to disease type and the
presence or spinal lesions could better clarify mechanism of
ts-DCS in MS.
CONCLUSION
In conclusion, our results suggest that ts-DCS may improve
central neuropathic pain in MS patients for up to 4 weeks.
Spinal DCS could be a promising, non-invasive, well-tolerated
and potentially self-administered treatment for neuropathic pain
in MS patients. This type of DCS may play a role as an add-on
treatment in drug-resistant pain or in patients who poorly
tolerate pharmacological treatment.
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